Keryx Biopharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$5.8M
Doctors Paid
3,670
Transactions
17,610
2018 Total
$4.0M
Payment Breakdown by Category
Research$4.2M (71.9%)
Food & Beverage$363,603 (6.3%)
Travel$280,931 (4.9%)
Consulting$264,603 (4.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.2M | 174 | 71.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $709,285 | 328 | 12.3% |
| Food and Beverage | $363,603 | 16,133 | 6.3% |
| Travel and Lodging | $280,931 | 667 | 4.9% |
| Consulting Fee | $264,603 | 110 | 4.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,100 | 1 | 0.0% |
| Grant | $2,000 | 1 | 0.0% |
| Gift | $364.91 | 120 | 0.0% |
| Education | $151.69 | 76 | 0.0% |
Payments by Type
Research
$4.2M
174 transactions
General
$1.6M
17,436 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| KRX-0502 Ferric Citrate in Subjects With NDD-CKD and IDA The COMPASS Trial COMPASS | $1.9M | 0 | 106 |
| Protocol 2014-FC-015 | $538,552 | 1 | 4 |
| 2015-FC-026 | $318,157 | 1 | 3 |
| Compass | $221,022 | 15 | 32 |
| Transition toFerric CitrateAmong Hemodialysis and Peritoneal Dialysis Patients | $218,426 | 0 | 2 |
| Ferric Citrate for the Transition From CKD Stage 45 to CKD Stage 5D 05D | $151,150 | 0 | 3 |
| CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease CRIC-VAP | $133,692 | 0 | 4 |
| 2015-FC-022 | $122,747 | 1 | 1 |
| 2017-FC-45 | $100,000 | 0 | 1 |
| Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency | $98,739 | 0 | 3 |
| Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease PIOPKD | $94,757 | 0 | 2 |
| 2015-FC-033 | $50,265 | 1 | 1 |
| Ferric Citrate in ESRD Pilot Project | $49,099 | 0 | 2 |
| 2015-FC-024 | $41,810 | 1 | 1 |
| 2015-FC-30 | $33,737 | 0 | 1 |
| IRB15017 | $16,753 | 1 | 4 |
| COMPASS | $14,339 | 0 | 1 |
| 2016-FC-037 | $9,510 | 0 | 1 |
| Protocol 0502-307 | $1,695 | 1 | 1 |
| 2014-FC-XX | $1,515 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Geoffrey Block, Md, MD | Nephrology | Lone Tree, CO | $583,221 | $0 |
| Victoria Kumar, Md, MD | Nephrology | Los Angeles, CA | $318,157 | $0 |
| Dr. Ramon Mendez, M.d, M.D | Nephrology | Woodbridge, VA | $142,390 | $0 |
| Sreedhar Mandayam, M.d, M.D | Nephrology | Houston, TX | $123,084 | $0 |
| Jay Wish, Md, MD | Nephrology | Indianapolis, IN | $90,820 | $0 |
| German Hernandez, M.d, M.D | Internal Medicine | El Paso, TX | $86,704 | $0 |
| Christopher Gisler, Md, MD | Internal Medicine | Pittsburgh, PA | $72,870 | $0 |
| Tomas Ganz, Md, MD | Pulmonary Disease | Los Angeles, CA | $51,605 | $0 |
| Abdul Abdellatif, M.d, M.D | Internal Medicine | Webster, TX | $46,478 | $0 |
| Dr. Pablo Pergola, Md, MD | Nephrology | San Antonio, TX | $44,587 | $0 |
| Orlando Gutierrez, M.d, M.D | Internal Medicine | Birmingham, AL | $43,409 | $0 |
| Dr. Mohit Ahuja, M.d, M.D | Nephrology | Flowood, MS | $32,063 | $0 |
| Manuel Montero, M.d, M.D | Nephrology | New Bern, NC | $30,953 | $0 |
| Dr. Nauman Shahid, M.d,, M.D, | Internal Medicine | Greenville, NC | $30,937 | $0 |
| John Manley, M.d, M.D | Nephrology | Asheville, NC | $24,586 | $0 |
| Dr. Richard Chan, Md, MD | Nephrology | New York, NY | $24,000 | $0 |
| Joseph Roglieri, D.o, D.O | Nephrology | Troy, NY | $22,927 | $0 |
| Nimish Naik, M.d, M.D | Nephrology | Wexford, PA | $22,429 | $0 |
| Dr. Padam Hirachan, Md, MD | Nephrology | Natchez, MS | $22,065 | $0 |
| Dr. Philip Sager, Md, MD | Cardiovascular Disease | San Francisco, CA | $21,465 | $0 |
| Dr. Shayan Shirazian, M.d, M.D | Internal Medicine | New York, NY | $20,902 | $0 |
| George Aronoff, Md, MD | Nephrology | Louisville, KY | $20,686 | $0 |
| Steven Fishbane, M.d, M.D | Specialist | Mineola, NY | $20,335 | $0 |
| Glenn Chertow, Md, MD | Internal Medicine | Stanford, CA | $20,050 | $0 |
| Dr. Navid Saigal, Md, MD | Nephrology | Live Oak, TX | $19,783 | $0 |
Ad
Top Products
- Auryxia $5.8M
Payment Categories
- Food & Beverage $363,603
- Consulting $264,603
- Travel & Lodging $280,931
- Research $4.2M
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. has made $5.8M in payments to 3,670 healthcare providers, recorded across 17,610 transactions in the CMS Open Payments database. In 2018, the company paid $4.0M. The top product by payment volume is Auryxia ($5.8M).
Payments were distributed across 39 medical specialties. The top specialty by payment amount is Nephrology ($2.2M to 2,638 doctors).
Payment categories include: Food & Beverage ($363,603), Consulting ($264,603), Research ($4.2M), Travel & Lodging ($280,931).